The London & Cambridge Life Sciences team advised Maxion Therapeutics on their $72 million Series A round. The round was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and Company and supported by existing investors LifeArc Ventures, Monograph Capital and BGF.
Maxion Therapeutics is the developer of a novel platform designed to generate antibody-like therapeutics called KnotBodies® to treat ion channel and GPCR-driven diseases.
The Goodwin team included David Mardle, Elizabeth Rhodes, Heidi McNally and George Fagan.
For additional details on the financing please see here.